Work

A randomized, double-blind, placebo-controlled trial of infliximab in refractory polymyositis and dermatomyositis

Year: 2017

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Seminars in Arthritis and Rheumatism

DOI: 10.1016/j.semarthrit.2017.10.010

Authors: Adam Schiffenbauer, Megha Garg, Christine Castro, Angelina Pokrovnichka, Galen Joe, Joseph Shrader, Imelda Victoria Cabalar, Sara Faghihi-Kashani, Michael O. Harris-Love, Paul H. Plotz, Frederick W. Miller, Mark Gourley

Institutions: National Institutes of Health, National Institute of Environmental Health Sciences, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health Clinical Center

Language: English

Topic: Inflammatory Myopathies and Dermatomyositis

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Associação Fundo de Incentivo à Pesquisa, National Institutes of Health

Award: G7295373465

OpenAlex ID: W2761661768

FWCI: 4.924

Cites: 40

Cited by: 72

Related to: 10